Welcome to our dedicated page for Genetic Technologies news (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies stock.
Genetic Technologies Limited (GENE) delivers innovative genomic risk assessment solutions through its geneType and EasyDNA platforms. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in predictive diagnostics, strategic collaborations, and regulatory milestones.
Access official press releases covering quarterly earnings, product validations, patent approvals, and partnership announcements. Our curated feed simplifies tracking of GENE’s progress in integrating genetic insights into clinical decision-making and consumer health programs.
Discover updates about the company’s molecular testing innovations, including developments in oncology risk stratification and population health initiatives. Content spans financial disclosures, research breakthroughs, and global expansion efforts across healthcare markets.
Bookmark this page for streamlined access to verified information about Genetic Technologies’ operational developments. Check regularly for new insights into how GENE continues shaping personalized medicine through advanced DNA analysis technologies.
Genetic Technologies (NASDAQ: GENE) has launched testing operations in the U.S. for its geneType genetic risk assessment product series. Utilizing the advanced facilities of Gene by Gene in Houston, the company aims to process up to 25,000 tests per month, enhancing operational capacity and reducing turnaround times for North American samples. This expansion is bolstered by a distribution agreement with Stayhealthy, expected to drive growth across North America. GeneType's tests, which are non-invasive and saliva-based, cover risks for nine diseases, including metabolic, cardiovascular, and oncological conditions. The collaboration aims to meet rising demand for personalized health information.
Genetic Technologies (GTG) and Stayhealthy have announced a distribution agreement to expand the reach of GTG's Multi-Risk Test throughout North America. The Multi-Risk Test will be available via StayHealthyRx, Stayhealthy's online pharmacy platform, which boasts 1.5 million users and comprehensive email outreach capabilities. This collaboration aims to empower individuals with personalized health risk assessments and actionable insights to improve their health. Both companies highlight the synergy between GTG's genetic testing expertise and Stayhealthy's technology-driven health solutions.
Genetic Technologies (ASX: GTG; NASDAQ: GENE) unveiled its innovative geneType Comprehensive Risk Assessment test, targeting 100% of women at risk of breast and ovarian cancer. This test, launched at the 'Know Your Risk' event in California, evaluates both hereditary and sporadic cancer risks for women over 30. The event, co-hosted by Dr. Kristi Funk and Krystal Barter, emphasized genomics' role in women's health. The geneType test represents a significant advancement in preventative healthcare, covering 1 in 8 women in the US at risk for breast cancer (310,000 annual diagnoses) and 19,600 ovarian cancer cases yearly. GTG's new high-throughput automated lab in the US can handle up to 100,000 tests per month, anticipating high demand.
GeneType and Humanise Health hosted the 'Know Your Risk' event on May 23, 2024, in Pasadena, California. This landmark event aimed to empower women through knowledge on genetic testing and risk assessment. Co-hosted by Dr. Kristi Funk and Krystal Barter, the event featured notable panelists who discussed the role of genomics in women's health. Key sessions included discussions on the gender health gap and patient advocacy. A major highlight was the launch of the GeneType hereditary breast and ovarian cancer test, which identifies all women at risk, including those with common gene mutations, regardless of family history. The event aimed to inspire proactive health advocacy among women.
Genetic Technologies (GTG) signed a strategic joint sales & marketing agreement with Wellworks for You Inc. to incorporate geneType tests into its employee wellness solutions, potentially generating 40,000 unit sales in year one. The partnership aims to provide geneType Risk Assessment Testing to Wellworks' 750 employer groups and 2 million covered lives, marking a pivotal milestone for both companies.
Genetic Technologies (GENE) released its Appendix 4C & Quarterly Business Update for Q3 FY24, showcasing key highlights such as cash receipts totaling A$1.8m, a significant increase in geneType adoption, launch of a Comprehensive Risk Assessment Test, and successful fund raising initiatives. The Company also reported on a successful DTC digital media sales campaign in the US and the establishment of a GeneType pilot study in US Breast Screen Imaging Centres.
